Clinical Trial Goal
To find out:
- The highest dose of EO2463 that’s safe to give with lenalidomide and/or rituximab
- If the combination of EO2463 and lenalidomide and/or rituximab is safe and works well to treat indolent NHL
You may be able to join this trial if you:
- Are 18 years or older
- Have one of the following types of indolent NHL:
- Follicular lymphoma
- Marginal zone lymphoma (MZL)
- Do not have grade 3b or transformed lymphoma. Your doctor can tell you this
- Have not been treated with EO2463. Your doctor can tell you this
- Do not have lymphoma in your brain or spinal cord
- Have not had an autologous (your own cells) blood or marrow transplant (BMT)
- Have not had an allogeneic (cells from a donor) BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Lenalidomide is a drug that blocks growth of cancer cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
EO2463 is a cancer peptide therapeutic vaccine that finds and targets lymphoma cells.
In this trial, you’ll be placed in 1 of 3 groups. You’ll be told what group you’re in:
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
EO2463 is a cancer peptide therapeutic vaccine that finds and targets lymphoma cells.
In this trial, you’ll be placed in 1 of 3 groups. You’ll be told what group you’re in:
- Group 1 – EO2463
- Group 2 – EO2463 plus rituximab
- Group 3 – EO2463 plus lanalidamide and rituximab
You'll get:
- EO2463 – Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
- Lenalidomide – Group 3 only – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Rituximab – Groups 2 and 3 only – Given as an intravenous (IV) infusion. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 2 years. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 7 years.
The Food and Drug Administration (FDA) has approved lenalidomide and rituximab to treat NHL. The FDA has not yet approved EO2463.
Contacts
Jan Fagerberg, MD, PhD, +32 3 205 55 55, medicalmonitoring-hem@enterome.com
Karlijn Kroon, MD, +33 611300589, kkroon-ext@enterome.com
Locations
Dana Farber Cancer InstituteRECRUITING
Boston, Massachusetts
Reid Merryman, Dr
Mayo ClinicRECRUITING
Rochester, Minnesota
Jose Caetano Villasboas Bisneto, Dr
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)RECRUITING
Rochester, New York
Jonathan Friedberg, Dr
University of Washington-Seattle Cancer Care AllianceRECRUITING
Seattle, Washington
Stephen Smith, Dr
Sponsors
lead: Enterome
